| Nasdaq: IMMU
Immunomedics, Inc. is a biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. The company's products include immuSTRIP HAMA Test Kit and LeukoScan. It has some clinical development products: Epratuzumab, Clivatuzumab, Veltuzamab and Milatuzumab. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ.